Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RNA-Targeted Therapeutics
Stanley T. Crooke, Joseph L. Witztum, C. Frank Bennett, et al.
Cell Metabolism (2018) Vol. 27, Iss. 4, pp. 714-739
Open Access | Times Cited: 680

Showing 1-25 of 680 citing articles:

Therapeutic siRNA: state of the art
Bo Hu, Liping Zhong, Yuhua Weng, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1103
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk, Ioanna Gouni‐Berthold, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 3, pp. 244-255
Open Access | Times Cited: 729
Principles for targeting RNA with drug-like small molecules
K.D. Warner, Christine E. Hajdin, Kevin M. Weeks
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 8, pp. 547-558
Open Access | Times Cited: 636
Circular RNAs: Characterization, cellular roles, and applications
Chu‐Xiao Liu, Ling‐Ling Chen
Cell (2022) Vol. 185, Iss. 12, pp. 2016-2034
Open Access | Times Cited: 623
Antisense technology: an overview and prospectus
Stanley T. Crooke, Brenda F. Baker, Rosanne M. Crooke, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 6, pp. 427-453
Closed Access | Times Cited: 501
Therapeutic Antisense Oligonucleotides Are Coming of Age
C. Frank Bennett
Annual Review of Medicine (2019) Vol. 70, Iss. 1, pp. 307-321
Open Access | Times Cited: 468
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Mitsuo Kato, Rama Natarajan
Nature Reviews Nephrology (2019) Vol. 15, Iss. 6, pp. 327-345
Open Access | Times Cited: 446
IL-17 receptor–based signaling and implications for disease
Xiaoxia Li, Rami Bechara, Junjie Zhao, et al.
Nature Immunology (2019) Vol. 20, Iss. 12, pp. 1594-1602
Open Access | Times Cited: 416
Chemistry, structure and function of approved oligonucleotide therapeutics
Martin Egli, Muthiah Manoharan
Nucleic Acids Research (2023) Vol. 51, Iss. 6, pp. 2529-2573
Open Access | Times Cited: 398
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics
Jayesh A. Kulkarni, Dominik Witzigmann, Sam Chen, et al.
Accounts of Chemical Research (2019) Vol. 52, Iss. 9, pp. 2435-2444
Open Access | Times Cited: 389
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Karishma Dhuri, Clara Bechtold, Elias Quijano, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 6, pp. 2004-2004
Open Access | Times Cited: 386
The growth of siRNA-based therapeutics: Updated clinical studies
M. May Zhang, Raman Bahal, Theodore P. Rasmussen, et al.
Biochemical Pharmacology (2021) Vol. 189, pp. 114432-114432
Open Access | Times Cited: 385
RNA-based therapeutics: an overview and prospectus
Yiran Zhu, Liyuan Zhu, Xian Wang, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 7
Open Access | Times Cited: 374
The Hippo signalling pathway and its implications in human health and diseases
Minyang Fu, Yuan Hu, Tianxia Lan, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 324
The challenge and prospect of mRNA therapeutics landscape
Yuhua Weng, Chunhui Li, Tongren Yang, et al.
Biotechnology Advances (2020) Vol. 40, pp. 107534-107534
Closed Access | Times Cited: 315
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Ai‐Ming Yu, Young Hee Choi, Mei‐Juan Tu
Pharmacological Reviews (2020) Vol. 72, Iss. 4, pp. 862-898
Open Access | Times Cited: 306
Lipid nanoparticle technology for therapeutic gene regulation in the liver
Dominik Witzigmann, Jayesh A. Kulkarni, Jerry Leung, et al.
Advanced Drug Delivery Reviews (2020) Vol. 159, pp. 344-363
Open Access | Times Cited: 280
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
C. Frank Bennett, Adrian R. Krainer, Don W. Cleveland
Annual Review of Neuroscience (2019) Vol. 42, Iss. 1, pp. 385-406
Open Access | Times Cited: 279
RNAi therapeutic and its innovative biotechnological evolution
Yuhua Weng, Haihua Xiao, Jinchao Zhang, et al.
Biotechnology Advances (2019) Vol. 37, Iss. 5, pp. 801-825
Closed Access | Times Cited: 250
Phosphorothioate modified oligonucleotide–protein interactions
Stanley T. Crooke, Timothy A. Vickers, Xue‐hai Liang
Nucleic Acids Research (2020) Vol. 48, Iss. 10, pp. 5235-5253
Open Access | Times Cited: 247
Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis
Soumik BasuRay, Yang Wang, Ēriks Šmagris, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 19, pp. 9521-9526
Open Access | Times Cited: 245
Antisense technology: A review
Stanley T. Crooke, Xue‐hai Liang, Brenda F. Baker, et al.
Journal of Biological Chemistry (2021) Vol. 296, pp. 100416-100416
Open Access | Times Cited: 236
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Dean G. Brown, Heike J. Wobst
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 5, pp. 2312-2338
Closed Access | Times Cited: 217
Resolution of coronavirus disease 2019 (COVID-19)
Khaled Habas, Chioma Nganwuchu, Fanila Shahzad, et al.
Expert Review of Anti-infective Therapy (2020) Vol. 18, Iss. 12, pp. 1201-1211
Closed Access | Times Cited: 209
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Veronica J. Alexander, Shuting Xia, Eunju Hurh, et al.
European Heart Journal (2019) Vol. 40, Iss. 33, pp. 2785-2796
Open Access | Times Cited: 204
Page 1 - Next Page

Scroll to top